BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 28069035)

  • 21. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
    Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
    J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.
    Morichika K; Karube K; Sakihama S; Watanabe R; Kawaki M; Nishi Y; Nakachi S; Okamoto S; Takahara T; Satou A; Shimada S; Shimada K; Tsuzuki T; Fukushima T; Morishima S; Masuzaki H
    Am J Surg Pathol; 2021 Jun; 45(6):832-840. PubMed ID: 33899787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targetable genetic alterations of
    Jain N; Hartert K; Tadros S; Fiskus W; Havranek O; Ma MCJ; Bouska A; Heavican T; Kumar D; Deng Q; Moore D; Pak C; Liu CL; Gentles AJ; Hartmann E; Kridel R; Smedby KE; Juliusson G; Rosenquist R; Gascoyne RD; Rosenwald A; Giancotti F; Neelapu SS; Westin J; Vose JM; Lunning MA; Greiner T; Rodig S; Iqbal J; Alizadeh AA; Davis RE; Bhalla K; Green MR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.
    Högfeldt T; Johnsson P; Grandér D; Bahnassy AA; Porwit A; Eid S; Österborg A; Zekri AR; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
    Leuk Lymphoma; 2014 May; 55(5):1158-65. PubMed ID: 23841503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ehrlichia chaffeensis TRP120-mediated ubiquitination and proteasomal degradation of tumor suppressor FBW7 increases oncoprotein stability and promotes infection.
    Wang JY; Zhu B; Patterson LL; Rogan MR; Kibler CE; McBride JW
    PLoS Pathog; 2020 Apr; 16(4):e1008541. PubMed ID: 32353058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
    Lu L; Zhu F; Zhang M; Li Y; Drennan AC; Kimpara S; Rumball I; Selzer C; Cameron H; Kellicut A; Kelm A; Wang F; Waldmann TA; Rui L
    Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E498-E505. PubMed ID: 29295936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrine suppresses cell growth of diffuse large B-cell lymphoma via inhibiting CaMKIIγ/c-Myc/CDK6 signaling pathway.
    Gu J; Wang X; Zhang L; Xiang J; Li J; Chen Z; Zhang Y; Chen J; Shen J
    BMC Complement Med Ther; 2021 Jun; 21(1):163. PubMed ID: 34088288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma.
    Scuto A; Kujawski M; Kowolik C; Krymskaya L; Wang L; Weiss LM; Digiusto D; Yu H; Forman S; Jove R
    Cancer Res; 2011 May; 71(9):3182-8. PubMed ID: 21521803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
    Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The F-box protein FBXL16 up-regulates the stability of C-MYC oncoprotein by antagonizing the activity of the F-box protein FBW7.
    Morel M; Shah KN; Long W
    J Biol Chem; 2020 Jun; 295(23):7970-7980. PubMed ID: 32345600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
    Solomon LA; Batista CR; DeKoter RP
    Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
    Takada M; Zhuang M; Inuzuka H; Zhang J; Zurlo G; Zhang J; Zhang Q
    Oncotarget; 2017 Jan; 8(4):6787-6795. PubMed ID: 28036276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
    Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
    Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
    Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.